Role of MicroRNAs in NAFLD/NASH

被引:74
|
作者
Szabo, Gyongyi [1 ]
Csak, Timea [1 ,2 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Med, LRB215,364 Plantat St, Worcester, MA 01605 USA
[2] Brookdale Univ Hosp & Med Ctr, 1 Brookdale Plaza, Brooklyn, NY 11212 USA
关键词
MicroRNAs; NASH; NAFLD; FATTY LIVER-DISEASE; OBSTRUCTIVE SLEEP-APNEA; NONALCOHOLIC STEATOHEPATITIS; ADIPOSE-TISSUE; CIRCULATING MICRORNAS; METABOLIC SYNDROME; URIC-ACID; GUT MICROBIOTA; HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL EXPRESSION;
D O I
10.1007/s10620-015-4002-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
MicroRNAs (miRNAs) are highly conserved, small, 18-25 nucleotide, non-coding RNAs that regulate gene expression at the post-transcriptional level. Each miRNA can regulate hundreds of target genes, and vice versa each target gene can be regulated by numerous miRNAs, suggesting a very complex network and explaining how miRNAs play pivotal roles in fine-tuning essentially all biological processes in all cell types in the liver. Here, we summarize the current knowledge on the role of miRNAs in the pathogenesis and diagnosis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with an outlook to the broader aspects of metabolic syndrome. Furthermore, we discuss the role of miRNAs as potential biomarkers and therapeutic targets in NAFLD/NASH.
引用
收藏
页码:1314 / 1324
页数:11
相关论文
共 50 条
  • [21] An Overview of NAFLD/NASH in Japan
    Kim, Soo Ryang
    Kim, Ke Ih
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2016, 136 (04): : 565 - 572
  • [22] NAFLD, NASH and liver cancer
    Michelotti, Gregory A.
    Machado, Mariana V.
    Diehl, Anna Mae
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (11) : 656 - 665
  • [23] Characteristics and diagnosis of NAFLD/NASH
    Hashimoto, Etsuko
    Taniai, Makiko
    Tokushige, Katsutoshi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 64 - 70
  • [24] NASH, NAFLD, what's that?
    Lecerf, Jean-Michel
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2022, 26 (03): : 80 - 80
  • [25] Noninvasive Diagnosis of NAFLD and NASH
    Piazzolla, Valeria Annarita
    Mangia, Alessandra
    CELLS, 2020, 9 (04)
  • [26] Obesity, NAFLD/NASH, and Diabetes
    Prattichizzo, Francesco
    Ceriello, Antonio
    Shah, Viral N.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 : S231 - S240
  • [27] Current management of NAFLD/NASH
    Cardoso, Ana Carolina
    de Figueiredo-Mendes, Claudio
    A. Villela-Nogueira, Cristiane
    LIVER INTERNATIONAL, 2021, 41 : 89 - 94
  • [28] Natural History of NAFLD/NASH
    Mattias Ekstedt
    Patrik Nasr
    Stergios Kechagias
    Current Hepatology Reports, 2017, 16 (4) : 391 - 397
  • [29] From NAFLD to NASH to fibrosis to HCC: Role of dendritic cell populations in the liver
    Tacke, Frank
    Yoneyama, Hiroyuki
    HEPATOLOGY, 2013, 58 (02) : 494 - 496
  • [30] DISSECTING THE ROLE OF MACROPHAGE INHIBITORY FACTOR (MIF) ON MURINE NAFLD/NASH MODEL
    Horiguchi, Norio
    Takizawa, Daichi
    Uehara, Daisuke
    Kobayashi, Takeshi
    Tojima, Hiroki
    Yamazaki, Yuichi
    Sato, Ken
    Gao, Bin
    Kakizaki, Satoru
    GASTROENTEROLOGY, 2018, 154 (06) : S1155 - S1155